Scott K. Reed

Partner
Reed Scott

Scott Reed is co-chair of Venable's IP Litigation – Life Sciences Group. Scott has served as lead trial counsel in complex patent litigations involving pharmaceuticals, biotechnology, chemicals, medical devices, and electronic and computer technologies, in bench and jury trials in federal and state court and in contested proceedings before the U.S. Patent and Trademark Office. Before joining Venable, Scott spent his entire career at Fitzpatrick, Cella, Harper & Scinto, where he chaired the Litigation Practice Group and served as a member of the Management Committee.

Experience

Representative Matters

  • Alkermes in Luye Pharma v. Alkermes and Alkermes and Janssen v. Luye Pharma (injectable suspensions, including a long-acting injection of risperidone used to treat schizophrenia)
  • Allergan in Allergan v. Aurobindo, Allergan v. Wilshire and Allergan v. Sometset (ophthalmic formulations of alcaftadine for once-daily treatment of allergic conjunctivitis)
  • Alnylam in Alnylam v. Silence Therapeutics (RNA interference (RNAi) therapeutic platform technology)
  • Astellas in Astellas v. Actavis, Sandoz, Sawai, Lupin, Zydus, Prinston, Aurobindo, Apotex and Windlas (polymorphism and compounds to treat overactive bladder)
  • Bausch Health in Bausch & Lomb v. Alcon and Bausch & Lomb v. Allergan (contact lens care products containing proteolytic enzymes and antimicrobial agents); Visx v. Bausch & Lomb (laser eye surgery); Allergan v. Bausch & Lomb (intraocular lenses); Allergan v. Bausch & Lomb (anti-glaucoma pharmaceuticals); Bausch & Lomb v. GNC, Bausch & Lomb v. Leiner, Bausch & Lomb v. Alcon, Bausch & Lomb v. Rexall, and Bausch & Lomb v. Vitamin Health (nutritional supplement to treat macular degeneration); Valeant v. Actavis (polymorphism and compounds to treat Irritable Bowel Syndrome with Diarrhea and Hepatic Encephalopathy); Bausch Health v. Sun (polymorphism and compounds to treat Travelers Diarrhea)); Bausch Health v. Sandoz (polymorphism and compounds to treat Irritable Bowel Syndrome with Diarrhea)
  • Bristol-Myers Squibb in Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers Squibb (fusion protein regulation of the immune system); Housey Pharmaceuticals v. Bristol-Myers Squibb (cell-based biotechnology assays); Zymogenetics v. Bristol-Myers Squibb (fusion proteins); and Regents of the University of Michigan and Repligen Corporation v. Bristol-Myers (rheumatoid arthritis pharmaceuticals)
  • Canon in Intellectual Ventures v. Canon (graphical user interface and image sensor technology); Honeywell v. Canon (autofocus camera technology); and Gross v. Canon (microprocessor technology and optical devices)
  • DuPont in Schneider v. DuPont and DuPont v. Cordis (polymeric balloon angioplasty materials)
  • Emory University in Emory University v. Glaxo Wellcome (anti-hepatitis pharmaceuticals) and Emory University v. Glaxo Wellcome and BioChem Pharma (anti-AIDS pharmaceuticals)
  • Genzyme in Bonecare and Genzyme v. Pentech, Eagle, Sandoz, Anchen, and Roxane (kidney disease pharmaceuticals); Bonecare and Genzyme v. Impax, Lupin, Endo, Teva, Watson, and Sandoz (kidney disease pharmaceuticals); Daiichi Sankyo and Genzyme v. Impax and Lupin (anti-cholesterol pharmaceuticals)
  • GlaxoSmithKline in GlaxoSmithKline v. Barr (prostate pharmaceuticals) and Pozen v. Par (migraine pharmaceuticals)
  • IBM in Berkeley v. IBM (personal computers) and Valutron v. IBM (point-of-sale devices)
  • Mitsui in 3M v. Mitsui (adhesive technology)
  • Novartis in Novartis v. Abbott (organ transplant cyclosporin pharmaceuticals)
  • Pfizer in Pfizer v. Barr (estrogen contraceptive pharmaceuticals) and Pfizer v. Barr (hormone replacement therapy pharmaceuticals)
  • Quebec Metal Powders in Hoeganaes v. Quebec Metal Powders (powder metallurgy)
  • Regeneron in Regeneron v. Genentech (macular degeneration pharmaceuticals) and Regeneron v. Merus (transgenic mice) 
  • Sanofi-Aventis in Sanofi v. Genentech (anti-cancer pharmaceuticals) and Sanofi v. Genentech (macular degeneration pharmaceuticals)
  • UCB in UCB v. Mylan, UCB v. Dr. Reddy’s, UCB v. Ivax, UCB v. Sandoz, and UCB v. Cobalt (epilepsy pharmaceuticals); UCB and Research Corporation Technologies v. Glemnmark (epilepsy pharmaceuticals) UCB v. KV, UCB v. Mallinckrodt, and UCB v. Teva (attention deficit disorder pharmaceuticals)
  • Union Carbide in BP v. Union Carbide (polyethylene processing technology)

Representative Clients

  • Alkermes
  • Allergan
  • Alnylam
  • Astellas Pharma
  • Bausch Health
  • Canon
  • Emory University
  • Gates Foundation
  • Genzyme
  • Regeneron
  • Sanofi
  • UCB

Insights

Credentials
+

Education

  • J.D. University of New Hampshire, Franklin Pierce Law Center 1987
    • Editorial Board (IDEA) Journal of Law and Technology
  • B.S. Chemistry and Economics Ursinus College 1984

Bar Admissions

  • New York
  • U.S. Patent and Trademark Office

Court Admissions

  • U.S. Court of Appeals for the Federal Circuit
  • U.S. District Court for the Southern District of New York
  • U.S. District Court for the Eastern District of New York
  • U.S. District Court for the Western District of New York

Recognition
+

Scott is known as a “consummate trial lawyer who discerns how to persuade the judge and jurors” and who produces “consistently excellent results” (IAM Patent 1000, 2012). He is a “versatile operator with extensive first-chair experience” (IAM Patent 1000, 2013) and brings “a lot of sage advice and experience” (Legal 500, 2012) as well as “his enthusiasm to cases, leading a professional team” (Legal 500, 2008).

  • The Best Lawyers in America, Litigation – Patent, 2016 – 2021
  • Corporate INTL Magazine, Global Award: IP Litigation Attorney of the Year, New York, 2017
  • Managing Intellectual Property, IP Star, 2014 – 2020
  • IAM Patent 1000, The World’s Leading Patent Professionals, 2012 – 2019
  • PLC Which Lawyer, IP: Patent Litigation, 2012
  • IAM 250, The World’s Leading Patent Litigators, 2011
  • Legal 500, Patent Litigation: Full Coverage, 2007 – 2010, 2012 – 2013, 2019 – 2020
  • Legal Media Group, The World’s Leading Patent Law Practitioners, 2007 – 2010
  • LMG Life Sciences, 2012 – 2020
  • Leaders League
    • Leading Attorney, Patent Litigation, New York, 2012, 2014 – 2015
    • Leading Attorney, Patent Litigation, Nationwide, 2014 – 2015
  • Super Lawyers, Top Litigator, Intellectual Property, New York Metro, 2013 – 2019